Koroner Kalp Hastalarında Asimetrik Dimetil Arjinin Düzeyleri Ve Dimetilarjinin Dimetilamino Hidrolaz Enziminin Genetic Polimorfizmi
Yükleniyor...
Dosyalar
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Koroner kalp hastalığı olan bireylerde genetik olarak polimorfizm olması kardiyovasküler olaylara yatkınlığı arttırabilir. Dimetilarjinin Dimetilamino Hidrolaz (DDAH) enziminde bu genetik değişimin saptanması ile bu hastalık grubunda daha ileri tedavi protokolleri geliştirilmesine katkı sağlamak için koroner kalp hastalarında Asimetrik Dimetil Arjinin (ADMA) seviyeleri ve DDAH 1 (E.C. 3.5.3.18) enziminin T87M mutasyonu incelendi.
Background: Genetic polymorphism may enhance the predisposition to cardiovascular events in patients with coronary heart disease (CHD). The aim of this study is to contribute further treatment protocol development via investigation serum ADMA levels and dimethylarginine dimethylaminohydrolase DDAH 1 (E.C. 3.5.3.18) T87M mutation of CHD patients. Material and Methods: 50 CHD patients and 50 healthy volunteers from Konya region were included to this study. Serum ADMA levels were analyzed by high performance liquid chromatograpy. DDAH (E.C. 3.5.3.18) T87M mutation were determined by PCR from extracted whole blood DNA samples. Results: ADMA levels were significantly higher in patient group compared to control group and there was no statistically diffference between groups for Arginine / ADMA ratio (p>0.001, p0.08 respectively). Triglyceride levels were significantly higher in patient group compared to control group (p0.033) and HDL- cholesterol levels were significantly lower in patient group compared to control group (p>0.001). In DDAH 1 T87M polymorphism gene analysis, there was only one heterozygote patient, the other participiants were wildtype. Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.
Background: Genetic polymorphism may enhance the predisposition to cardiovascular events in patients with coronary heart disease (CHD). The aim of this study is to contribute further treatment protocol development via investigation serum ADMA levels and dimethylarginine dimethylaminohydrolase DDAH 1 (E.C. 3.5.3.18) T87M mutation of CHD patients. Material and Methods: 50 CHD patients and 50 healthy volunteers from Konya region were included to this study. Serum ADMA levels were analyzed by high performance liquid chromatograpy. DDAH (E.C. 3.5.3.18) T87M mutation were determined by PCR from extracted whole blood DNA samples. Results: ADMA levels were significantly higher in patient group compared to control group and there was no statistically diffference between groups for Arginine / ADMA ratio (p>0.001, p0.08 respectively). Triglyceride levels were significantly higher in patient group compared to control group (p0.033) and HDL- cholesterol levels were significantly lower in patient group compared to control group (p>0.001). In DDAH 1 T87M polymorphism gene analysis, there was only one heterozygote patient, the other participiants were wildtype. Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.
Açıklama
Anahtar Kelimeler
Genel ve Dahili Tıp, Koroner Kalp Hastalığı, Dimetilarjinin Dimetilamino Hidrolaz, Genetik Polimorfizm, Risk Değerlendirmesi, Coronary Heart Disease, Dimethylarginine Dimethylaminohydrolase, Genetic Polymorphism, Risk Assesment
Kaynak
Yeni Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
31
Sayı
3
Künye
Abuşoğlu, S., Ünlü, A., Çelik, H. T., Taner, A., Kayrak, M., Öç, M. A. H. (2014). Koroner kalp hastalarında asimetrik dimetil arjinin düzeyleri ve dimetilarjinin dimetilamino hidrolaz enziminin genetic polimorfizmi. Yeni Tıp Dergisi, 31, 3, 192-197.
